样式: 排序: IF: - GO 导出 标记为已读
-
-
KECORT Study: An International e-Delphi Study on the Treatment of KEloids Using Intralesional CORTicosteroids in Clinical Practice Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-09-19 Qi Yin, Albert Wolkerstorfer, Oren Lapid, Khatera Qayumi, Murad Alam, Firas Al-Niaimi, Ofir Artzi, Martijn B. A. van Doorn, Ioannis Goutos, Merete Haedersdal, Chao-Kai Hsu, Woraphong Manuskiatti, Stan Monstrey, Thomas A. Mustoe, Rei Ogawa, David Ozog, Tae Hwan Park, Julian Pötschke, Anthony Rossi, Swee T. Tan, Luc Téot, Fiona M. Wood, Nanze Yu, Susan Gibbs, Frank B. Niessen, Paul P. M. van Zuijlen
-
Update on Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Diagnosis and Management Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-09-15 Hemali Shah, Rose Parisi, Eric Mukherjee, Elizabeth J. Phillips, Roni P. Dodiuk-Gad
-
Predicting the Time to Relapse Following Withdrawal from Different Biologics in Patients with Psoriasis who Responded to Therapy: A 12-Year Multicenter Cohort Study Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-09-16 Yu-Huei Huang, Sung Jen Hung, Chaw-Ning Lee, Nan-Lin Wu, Rosaline Chung-yee Hui, Tsen-Fang Tsai, Chang-Ming Huang, Hsien-Yi Chiu
-
A Practice Approach to Acne Fulminans in Adolescents Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-09-13 Nicolas G. Quan, Remie Chrabieh, Mona Sadeghpour, Lucinda L. Kohn
-
Image-Based Artificial Intelligence in Psoriasis Assessment: The Beginning of a New Diagnostic Era? Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-09-11 Elisabeth V. Goessinger, Philippe Gottfrois, Alina M. Mueller, Sara E. Cerminara, Alexander A. Navarini
-
Predictors and Management of Inadequate Response to JAK Inhibitors in Alopecia Areata Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-09-03 Xiaolin Zhang, Yiqun Jiang
-
Advances in the Application of Noninvasive Skin Imaging Techniques in Acne Scars Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-08-12 Xiaoli Ning, Lingfan Jiang, Ruixing Yu, Yujun Sheng, Mengmeng Li, Hongfei Ouyang, Jingkai Xu, Yong Cui
-
Association of Cardiovascular Disease and Chronic Spontaneous Urticaria: A Case-Control Study. Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-08-05 Luis F Andrade,Zaim Haq,Parsa Abdi,Sarah G Brooks,Veronica Voronina,Michael J Diaz,Gil Yosipovitch
-
Dapsone Use in Dermatology Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-07-30 Katie K. Lovell, Rushan I. Momin, Harneet Singh Sangha, Steven R. Feldman, Rita O. Pichardo
Dapsone, initially synthesized for textile dyeing, gained recognition in the 1930s for its antibacterial properties, leading to its utilization in dermatology for leprosy and dermatitis herpetiformis. Despite US Food and Drug Administration (FDA) approval for these conditions, dapsone’s off-label uses have expanded, making it a valuable option in various dermatologic conditions. This review seeks to
-
Hidradenitis Suppurativa: New Targets and Emerging Treatments Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-07-26 Julia L. Gao, Tracey S. Otto, Martina L. Porter, Alexa B. Kimball
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that can be challenging to treat. Biologics and targeted small molecules have become an increasingly popular area of investigation for therapeutic development for moderate-to-severe HS, though only three biologics—adalimumab, secukinumab, and bimekizumab—have received US Food and Drug Administration (FDA) or European Medicines Evaluation
-
Sequencing of Targeted Therapy in Psoriasis: Does it Matter? Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-07-13 Nicole D. Boswell, Shikha Singla, Kenneth B. Gordon
-
Lichen Planus: What is New in Diagnosis and Treatment? Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-07-09 Burak Tekin, Fangyi Xie, Julia S. Lehman
-
Clinical Efficacy and Safety of Interleukin-17 Inhibitors in Treating Patients with Erythrodermic Psoriasis: A Retrospective Cohort, Three-Center Study. Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-07-05 Yu Lan,Xiaoyan Wu,Linya Ni,Yuhua Liu,Tianmeng Yan,Dejian Duan,Zhenying Zhang
-
Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-07-02 Yukari Okubo, Satomi Kobayashi, Masamoto Murakami, Shigetoshi Sano, Natsuko Kikuta, Yoshiumi Ouchi, Tadashi Terui
-
Human Inborn Errors of Immunity in Pyoderma Gangrenosum: A Systematic Review Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-07-01 Yasmine Oprea, Daniel R. Antohi, Morgan Vague, Caroline Delbourgo Patton, Benedict Wu, Alex G. Ortega‐Loayza
-
Association Between Biologic Exposure and the Risk of Depression in Patients with Psoriasis: A Retrospective Analysis of Large US Administrative Claims Data Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-06-27 Bruce Strober, Ahmed M. Soliman, Bang Truong, Manish B. Patel, Yazan K. Barqawi, Paolo Gisondi
-
The Current State of Systemic Therapy of Metastatic Uveal Melanoma Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-06-22 Elias A. T. Koch, Markus V. Heppt, Carola Berking
-
Evaluation of the Tolerability of Hedgehog Pathway Inhibitors in the Treatment of Advanced Basal Cell Carcinoma: A Narrative Review of Treatment Strategies Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-06-19 Aaron S. Farberg, Dustin Portela, Divya Sharma, Meenal Kheterpal
-
An Update on New and Existing Treatments for the Management of Melasma Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-06-19 Christian Gan, Michelle Rodrigues
Melasma is a chronic, acquired disorder of focal hypermelanosis that carries significant psychosocial impact and is challenging for both the patient and the treating practitioner to manage in the medium to long term. Multiple treatments have been explored, often in combination given the many aetiological factors involved in its pathogenesis. Therapeutic discoveries to treat melasma are a focal topic
-
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-06-18 Eric L. Simpson, Jonathan I. Silverberg, Audrey Nosbaum, Kevin Winthrop, Emma Guttman-Yassky, Karin M. Hoffmeister, Alexander Egeberg, Hernan Valdez, Haiyun Fan, Saleem A. Farooqui, Gary Chan, Justine Alderfer, William Romero, Kanti Chittuluru
-
Adherence to Hidradenitis Suppurativa Treatment Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-06-11 Caitlyn B. Dagenet, Swetha Atluri, Elaine Ma, Lauren Tong, Khiem A. Tran, Joshua Hekmatajah, Rahul Masson, Jennifer L. Hsiao, Vivian Y. Shi
-
Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-05-27 Sarah E. Thomas, Marieke M. B. Seyger, Josje E. Mangnus, Marisol E. Otero, Antoni H. Gostynski, Marcellus D. Njoo, Paul M. Ossenkoppele, Inge M. Haeck, Judith H. J. Hendricksen-Roelofzen, John E. M. Körver, Sharon R. P. Dodemont, Ron A. Tupker, Maartje A. M. Berends, Lizelotte M. J. T. Weppner-Parren, Romy R. M. C. Keijsers, Annet M. Oostveen, Bas Peters, Roland Mommers, Martijn B. A. van Doorn, Milan
-
The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-05-20 Jolanta Pach, Kailyn Valido, Annika Belzer, Jonathan S. Leventhal
Cutaneous immune-related adverse events encompass a spectrum of dermatological manifestations, including lichenoid reactions, psoriasiform eruptions, eczematous dermatitis, immunobullous disorders, granulomatous reactions, pruritus, vitiligo, and severe cutaneous adverse reactions such as Stevens–Johnson syndrome. The conventional approach to treating high-grade or refractory cutaneous immune-related
-
Management and Long-Term Outcomes of Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS) in Children: A Scoping Review Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-05-16 Nicole Cherepacha, Frances St George-Hyslop, Bindiya Chugani, Yousef Alabdeen, Luis F. Sanchez-Espino, Quenby Mahood, Cathryn Sibbald, Ruud H. J. Verstegen
-
Approach to the Atypical Wound Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-05-14 Sarah L. Becker, Shannon Kody, Nicole M. Fett, Alexander Hines, Afsaneh Alavi, Alex G. Ortega-Loayza
-
Managing the Patient with Psoriasis and Metabolic Comorbidities Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-05-15 Francesco Bellinato, Martina Maurelli, Davide Geat, Giampiero Girolomoni, Paolo Gisondi
-
Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-05-14 Amy S. Paller, Elaine C. Siegfried, Eric L. Simpson, Michael J. Cork, Robert Sidbury, Iris H. Chen, Faisal A. Khokhar, Jing Xiao, Ariane Dubost-Brama, Ashish Bansal
-
Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-05-02 Lawrence F. Eichenfield, Eric L. Simpson, Kim Papp, Jacek C. Szepietowski, Andrew Blauvelt, Leon Kircik, Jonathan I. Silverberg, Elaine C. Siegfried, Michael E. Kuligowski, May E. Venturanza, Howard Kallender, Haobo Ren, Amy S. Paller
-
Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-04-22 Jürgen C. Becker, Andreas Stang, David Schrama, Selma Ugurel
-
Ultrasound Surveillance in Melanoma Management: Bridging Diagnostic Promise with Real-World Adherence: A Systematic Review and Meta-Analysis Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-04-18 Zhao Feng Liu, Amy Sylivris, Johnny Wu, Darren Tan, Samuel Hong, Lawrence Lin, Michael Wang, Christopher Chew
-
Secondary Bacterial Infections in Patients with Atopic Dermatitis or Other Common Dermatoses Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-04-05 Romain Salle, Pascal Del Giudice, Charbel Skayem, Camille Hua, Olivier Chosidow
-
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2) Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-03-25 Jonathan I. Silverberg, Melinda J. Gooderham, Amy S. Paller, Mette Deleuran, Christopher G. Bunick, Linda F. Stein Gold, DirkJan Hijnen, Brian M. Calimlim, Wan-Ju Lee, Henrique D. Teixeira, Xiaofei Hu, Shiyu Zhang, Yang Yang, Ayman Grada, Andrew M. Platt, Diamant Thaçi
-
Expert Panel Review of Skin and Hair Dermatophytoses in an Era of Antifungal Resistance Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-03-18 Rachel C. Hill, Avrom S. Caplan, Boni Elewski, Jeremy A. W. Gold, Shawn R. Lockhart, Dallas J. Smith, Shari R. Lipner
-
Tree-Based Machine Learning to Identify Predictors of Psoriasis Incidence at the Neighborhood Level: A Populational Study from Quebec, Canada Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-03-18 Anastasiya Muntyanu, Raymond Milan, Mohammed Kaouache, Julien Ringuet, Wayne Gulliver, Irina Pivneva, Jimmy Royer, Max Leroux, Kathleen Chen, Qiuyan Yu, Ivan V. Litvinov, Christopher E. M. Griffiths, Darren M. Ashcroft, Elham Rahme, Elena Netchiporouk
-
Management of Acne in Pregnancy Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-03-07 Akash Rau, Jonette Keri, Jenny E. Murase
Acne is one of the most common dermatological conditions to affect women of childbearing age, so it is important to consider the safety of long-term acne treatments on women who could become pregnant. In this review article, we clarify what management options are available to treat acne during pregnancy. Topical treatments, typically first-line for acne, such as azelaic acid, clindamycin, erythromycin
-
Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-03-04 I-Hsin Huang, Po-Chien Wu, Hsien-Yi Chiu, Yu-Huei Huang
-
Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-02-26 Ryan C. Augustin, Jason J. Luke
-
The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-02-16 Annika Belzer, Jolanta J. Pach, Kailyn Valido, Jonathan S. Leventhal
-
Field Cancerization Therapies for the Management of Actinic Keratosis: An Updated Review Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-02-13 Ishita Aggarwal, Carolina Puyana, Neha Chandan, Nathan Jetter, Maria Tsoukas
Field cancerization theory highlights that the skin surrounding actinic keratoses (AK) is also at increased risk for possible malignant transformation; thus, field-directed treatments may both reduce the risk of AK recurrence and potentially reduce the risk of development of cutaneous squamous cell carcinoma (cSCC). Photodynamic therapy (PDT) with either aminolevulinic acid (ALA) or methylaminolevulinate
-
Autoimmune, Autoinflammatory Disease and Cutaneous Malignancy Associations with Hidradenitis Suppurativa: A Cross-Sectional Study Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-02-09 Hilliard T. Brydges, Ogechukwu C. Onuh, Rebecca Friedman, Joy Barrett, Rebecca A. Betensky, Catherine P. Lu, Avrom S. Caplan, Afsaneh Alavi, Ernest S. Chiu
Background Hidradenitis suppurativa (HS) is a debilitating cutaneous disease characterized by severe painful inflammatory nodules/abscesses. At present, data regarding the epidemiology and pathophysiology of this disease are limited. Objective To define the prevalence and comorbidity associations of HS. Methods This was a cross-sectional study of EPICTM Cosmos© examining over 180 million US patients
-
Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-02-08 Alexandra Haugh, Adil I. Daud
-
Autoimmune and Cutaneous Inflammatory Comorbidities in Adult-Onset Morphea in the All of Us Research Program. Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-02-02 Jill T Shah,William Mark Richardson,Lavanya Mittal,Emily Hejazi,Daniel R Mazori,Alisa N Femia
-
Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-01-24 Tiago Torres, Andrea Chiricozzi, Luis Puig, Ana Maria Lé, Angelo Valerio Marzano, Paolo Dapavo, Esteban Dauden, Jόse-Manuel Carrascosa, Elizabeth Lazaridou, Gleison Duarte, André V. E. Carvalho, Ricardo Romiti, Natalia Rompoti, Laetitia Teixeira, Miguel Abreu, Elena Ippoliti, Carlo Alberto Maronese, Mar Llamas-Velasco, Eva Vilarrasa, Elena del Alcázar, Athina-Ioanna Daponte, Marina Papoutsaki, Andrea
Background Tuberculosis has a major global impact. Immunocompetent hosts usually control this disease, resulting in an asymptomatic latent tuberculosis infection (LTBI). Because TNF inhibitors increase the risk of tuberculosis reactivation, current guidelines recommend tuberculosis screening before starting any biologic drug, and chemoprophylaxis if LTBI is diagnosed. Available evidence from clinical
-
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-01-23 Brett King, Jennifer Soung, Christos Tziotzios, Lidia Rudnicka, Pascal Joly, Melinda Gooderham, Rodney Sinclair, Natasha A. Mesinkovska, Carle Paul, Yankun Gong, Susan D. Anway, Helen Tran, Robert Wolk, Samuel H. Zwillich, Alexandre Lejeune
-
The Skin Microbiome and its Significance for Dermatologists Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-01-22 Cleo Whiting, Sara Abdel Azim, Adam Friedman
-
Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-01-19 Wilson Hu, Michele Thornton, Robert A. Livingston
Background Ruxolitinib cream is the first topical Janus kinase (JAK) inhibitor approved in the United States (US) for the treatment of mild to moderate atopic dermatitis and nonsegmental vitiligo. A postmarketing study with oral tofacitinib, approved for rheumatoid arthritis, triggered class warnings for JAK inhibitors, including risk of serious infections, mortality, malignancy, major adverse cardiovascular
-
OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-01-18 Michael Croft, Ehsanollah Esfandiari, Camilla Chong, Hailing Hsu, Kenji Kabashima, Greg Kricorian, Richard B. Warren, Andreas Wollenberg, Emma Guttman-Yassky
-
Mucocutaneous Manifestations of Recreational Drug Use Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-01-13 Carolina V. Alexander-Savino, Ginat W. Mirowski, Donna A. Culton
-
Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2024-01-12 Richard W. Kim, Megan Lam, Katrina Abuabara, Eric L. Simpson, Aaron M. Drucker
Therapeutic options for people with moderate or severe atopic dermatitis refractory to topical therapy have rapidly expanded in recent years. These new targeted immunomodulatory agents—biologics and Janus kinase (JAK) inhibitors—have each demonstrated high levels of efficacy and acceptable safety in mostly placebo-controlled clinical trials for atopic dermatitis, but there is no universally applicable
-
Pressure and Skin: A Review of Disease Entities Driven or Influenced by Mechanical Pressure Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2023-12-30 Wei-Chen Chien, Tsen-Fang Tsai
-
Pityriasis Rubra Pilaris: An Updated Review of Clinical Presentation, Etiopathogenesis, and Treatment Options Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2023-12-30 Tejas P. Joshi, Madeleine Duvic
-
Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2023-12-29 Meropi Karakioulaki, Kilian Eyerich, Aikaterini Patsatsi
-
Rare Autoinflammatory Neutrophilic Dermatoses in Pregnancy: Literature Review Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2023-12-13 Angela Lo, Brittany Thompson, Naveed Sami
Rare cases of autoinflammatory neutrophilic dermatoses (AINDs) have been reported in patients during pregnancy with associated adverse maternal and fetal outcomes. Due to the rarity and heterogeneous morphology of pregnancy-associated AINDs, clinical diagnosis is often overlooked, and treatment options are limited. In this review, we present the epidemiology, clinical characteristics, therapeutic interventions
-
Recent Advances in Treatment of Systemic Sclerosis and Morphea Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2023-12-12 Noelle Teske, Nicole Fett
-
Treat-to-Target in Atopic Dermatitis Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2023-12-11 Christian Vestergaard, Catalina Skovsgaard, Claus Johansen, Mette Deleuran, Jacob P. Thyssen
-
Review of Teledermatology: Lessons Learned from the COVID-19 Pandemic Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2023-12-07 Jonathan K. Hwang, Natalia Pelet del Toro, George Han, Dennis H. Oh, Trilokraj Tejasvi, Shari R. Lipner
Utilization of telemedicine for dermatology has greatly expanded since the start of the COVID-19 pandemic, with over 500 new teledermatology studies published since 2020. An updated review on teledermatology is necessary to incorporate new findings and perspectives, and educate dermatologists on effective utilization. We discuss teledermatology in terms of diagnostic accuracy and clinical outcomes
-
Photodynamic Therapy in Treating a Subset of Basal Cell Carcinoma: Strengths, Shortcomings, Comparisons with Surgical Modalities, and Potential Role as Adjunctive Therapy Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2023-12-02 Maggie Chen, Albert Zhou, Amor Khachemoune
-
What’s New in Cutaneous T-Cell Lymphoma-Associated Pruritus Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2023-11-16 Georgia Biazus Soares, Joan Guitart, Gil Yosipovitch
-
Non-invasive Skin Imaging in Cutaneous Lymphomas Am. J. Clin. Dermatol. (IF 8.6) Pub Date : 2023-11-14 Eyal Taleb, Oriol Yélamos, Marco Ardigo, Rachel E. Christensen, Shamir Geller